Inovio Pharmaceuticals Stock News

No one knows which of the many vaccine candidates will be safe and effective, but Inovio's unique approach has left it without a major manufacturing contract. The post Inovio Becomes a Covid-19 Longs

Encouraging preliminary results for its Covid-19 vaccine and its budding HPV solutions make INO stock a great bet at this stage. The post Inovio Pharmaceuticals Stock Isn’t Just a Solid Covid-19 Pl

Hope for a successful vaccine by the winter is fueling trials at a record pace.

CureVac (NASDAQ: CVAC) held its initial public offering (IPO) on the Nasdaq stock exchange last week. CureVac expected the IPO share price would be between $14 and $16. Here's what you'll want to k

With more competition in the vaccine race, INO stock lost much of its sheen. But don’t rule out Inovio Pharmaceuticals because it has critical advantages that others lack.

This stock has skyrocketed this year as part of the COVID-19 vaccine development race, but will the momentum continue?

Inovio Pharmaceuticals (NASDAQ: INO) has enjoyed a remarkable year so far by any standard. Inovio's shares have skyrocketed close to 350%. A lot could happen to derail the company's fast track to su

This stock has skyrocketed this year as part of the COVID-19 vaccine development race, but will the momentum continue?

The small biotech has some big hurdles to jump over the next few months.

Buying shares in this small-cap biotech hasn't made long-term investors rich -- at least, not yet.

Buy shares of a company that isn't profitable yet and doesn't even have consistent revenue. Inovio Pharmaceuticals (NASDAQ: INO) definitely fits the bill of a company that isn't generating a profit r

On Friday, shares of Inovio Pharmaceuticals (NASDAQ: INO) saw unusual options activity. After the option alert, the stock price moved up to $15.5. * Sentiment: BEARISH * Option Type: SWEEP * Trade

2020 is turning out to be a tale of two halves for Inovio Pharmaceuticals (INO).The vaccine maker's valuation increased 10-fold between January and early July, backed by vigorous coronavirus tailwinds

After a rough week on the stock market for the biotech company, investors finally think the price is right.

Inovio’s Q2 earnings and lingering questions about its INO-4800 vaccine are combining for a big drop for INOP stock. The post Inovio Pharmaceuticals Shares Drop, Get a Downgrade appeared first on In